A randomized trial of ibrutinib and R-GDP prior to stem cell transplant in relapsed diffuse large B-cell lymphoma

John Kuruvilla; Christopher Rushton; Diego Villa; Muhammad Aslam; Anca Prica; Nizar Abdel Samad; Stephane Doucet; Jill Dudebout; Isabelle Fleury; Graeme Fraser; Jean-Francois Larouche; Mona Shafey; Pamela Skrabek; Tanya Skamene; Ryan D Morin; Miguel Alcaide; Susana Ben-Neriah; David Lee; Chad Winch; Lois E Shepherd; David W Scott; Michael Crump; Bingshu E Chen; Annette E Hay

doi:10.1111/bjh.19764

A randomized trial of ibrutinib and R-GDP prior to stem cell transplant in relapsed diffuse large B-cell lymphoma

Br J Haematol. 2024 Nov;205(5):2067-2071. doi: 10.1111/bjh.19764. Epub 2024 Sep 12.

Authors

John Kuruvilla¹, Christopher Rushton², Diego Villa³, Muhammad Aslam⁴, Anca Prica¹, Nizar Abdel Samad⁵, Stephane Doucet⁶, Jill Dudebout⁷, Isabelle Fleury⁸, Graeme Fraser⁹, Jean-Francois Larouche¹⁰, Mona Shafey¹¹, Pamela Skrabek¹², Tanya Skamene¹³, Ryan D Morin², Miguel Alcaide², Susana Ben-Neriah¹⁴, David Lee¹⁵, Chad Winch¹⁶, Lois E Shepherd¹⁶, David W Scott³, Michael Crump¹, Bingshu E Chen¹⁶, Annette E Hay¹⁶

Affiliations

¹ Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
² Simon Fraser University, Burnaby, British Columbia, Canada.
³ BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, British Columbia, Canada.
⁴ Hematology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
⁵ Hematology, The Moncton Hospital, Moncton, New Brunswick, Canada.
⁶ Hematologic Oncology, CHUM-Hopital Notre-Dame, Montreal, Quebec, Canada.
⁷ Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Ontario, Canada.
⁸ Hematologic Oncology, Maisonneuve Rosemont Hospital, University of Montreal, Montreal, Quebec, Canada.
⁹ Hematology, Juravinski Cancer Centre, Hamilton, Ontario, Canada.
¹⁰ CHU de Quebec-Universite Laval, Quebec City, Quebec, Canada.
¹¹ Alberta Health Services, University of Calgary, Calgary, Alberta, Canada.
¹² Section of Hematology/Oncology Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
¹³ Jewish General Hospital, Montreal, Quebec, Canada.
¹⁴ BC Cancer Centre for Lymphoid Cancer, Vancouver, British Columbia, Canada.
¹⁵ Department of Medicine, Queen's University, Kingston, Ontario, Canada.
¹⁶ Canadian Cancer Trials Group, Queen's University, Kingston, Ontario, Canada.

PMID: 39267295
DOI: 10.1111/bjh.19764

Abstract

In the LY.17 randomized phase II clinical trial, adults with relapsed and refractory diffuse large B-cell lymphoma treated with ibrutinib-R-GDP (IR-GDP) for up to three cycles had more documented bacterial and fungal infections, without improvement in overall response, compared with R-GDP. CR, complete response; DLBCL, diffuse large B-cell lymphoma; PD, progressive disease; PR, partial response; R/R, relapsed/refractory; SD, stable disease.

Publication types

Randomized Controlled Trial
Clinical Trial, Phase II
Multicenter Study
Letter

MeSH terms

Adenine* / analogs & derivatives
Adenine* / therapeutic use
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Female
Hematopoietic Stem Cell Transplantation
Humans
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Male
Middle Aged
Piperidines* / therapeutic use
Pyrazoles / administration & dosage
Pyrazoles / therapeutic use
Pyrimidines / administration & dosage
Pyrimidines / therapeutic use
Recurrence

Substances

ibrutinib
Adenine
Piperidines
Pyrimidines
Pyrazoles

Abstract

Publication types

MeSH terms

Substances

Grants and funding